AASLD News

AASLD's three practice guidelines on Non-Invasive Liver Disease Assessment (NILDA) are available for public comment through 1/2/24. The draft guidelines are included in three guideline documents expected to be published in early 2024: AASLD Practice Guideline: Blood-Based Non-invasive Liver Disease Assessment of Hepatic Fibrosis and Steatosis . You can provide your comments on this document here

AASLD, ACG, AGA, ASGE and NASPGHAN recognize that the new class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, tirzepatide, exenatide, liraglutide, albiglutide, dulaglutide, and lixisneatide, currently used for treatment of diabetes and/or weight loss, may be associated with delayed gastric emptying. There is concern that this class of medication

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society supporter of liver disease research and training in the United States, announced today it will distribute $2 million in 2023 to nearly 150 grant recipients to support liver-related research, bolster the pipeline of future hepatologists, and increase patient access to specialty

As AASLD President, it is with immense pleasure and pride that I write to you today to inform you of the next steps for the adoption of NAFLD’s new nomenclature: Steatotic Liver Disease (SLD). As you’re likely aware, the decision to adopt the term Steatotic Liver Disease as the preferred nomenclature was the result of extensive global deliberations and consultations by AASLD, EASL and ALEH along

The American Association for the Study of Liver Diseases (AASLD) acknowledges the important open letter by Rainbows in Gastro calling for a collective effort to support the safety and wellbeing of transgender and non-conforming members. We recognize that transgender and non-conforming individuals face unique challenges, including discrimination, stigma, and health disparities, and we are committed

Steatotic liver disease (SLD) is the new overarching term with metabolic dysfunction-associated steatotic liver disease (MASLD) replacing nonalcoholic fatty liver disease (NAFLD) Vienna, Austria, June 24 - At EASL Congress 2023, the multinational liver societies leaders from La Asociación Latinoamericana para el Estudio del Hígado (ALEH), American Association for the Study of Liver Diseases (AASLD

The American Association for the Study of Liver Diseases (AASLD), the leading organization of scientists and health care professionals committed to preventing and curing liver disease, calls on Congress to adopt legislation to allocate funds to eliminate hepatitis C. Improved access to testing stands to relieve the burden of hepatitis C, by increasing identification of those with the disease. This

Promoting Liver Health Awareness and Prevention of Liver Diseases Globally The European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the Asian Pacific Association for the Study of the Liver (APASL),the Asociacion Latinoamericana para el Estudio del Higado (ALEH), and the Society of Liver Disease in Africa (SOLDA) jointly call on

Don’t miss your chance to be here for all the exciting possibilities AASLD has prepared robust programming at DDW 2023 and is excited to engage the hepatology and GI communities. You too can be a Know-It-All, because at DDW you can learn it all! Although the early bird deadline has passed, there’s still plenty of time to register for Digestive Disease Week ® (DDW) 2023 . Make sure you’re here for

AASLD is pleased to announce the selection of thirty hepatology leaders as Fellows and two allied health leaders focused on hepatology as Associate Fellows. The Fellows Programs bestows honorary recognition upon AASLD members who have made a significant contribution to the knowledge and/or practice of liver and biliary diseases, and are considered leaders in the field. Associate Fellow of the

ALEXANDRIA, VA – The American Association for the Study of Liver Diseases (AASLD) applauds the White House for including a bold five-year plan to eliminate hepatitis C in the Fiscal Year 2024 budget request. We are pleased to support this plan which calls for the acceleration of the availability of point-of-care diagnostic tests, the expansion of access to curative therapies, and the

The American Association for the Study of Liver Diseases (AASLD) is deeply saddened to hear about the Kahramanmaras earthquake that has caused thousands of injuries and deaths, and widespread devastation in Turkey and Syria. Our thoughts and prayers go out to those impacted by this terrible tragedy. The AASLD – TASL CONNECT event was set to take place on February 10-11, 2023 in Ankara, Turkey, and

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) is pleased to announce that Dr. Joseph K. Lim, MD, FAASLD of Yale University will serve as the next Editor-in-Chief of Clinical Liver Disease ( CLD ), a free multimedia review journal that aims to provide education for clinicians diagnosing and managing patients with liver disease. Dr. Lim is a Professor of Medicine

AASLD Hepatology Award with Harold Amos Medical Faculty Development Program Applications Open February 8 In support of our unwavering commitment to champion diversity, equity, and inclusion in the field of hepatology, AASLD is pleased to announce the development of our own hepatology award. We have partnered with the Robert Wood Johnson Foundation’s Harold Amos Medical Faculty Development Program